This week in oncology biotech saw significant dealmaking, with Merck, Eli Lilly, and Biogen committing over $12 billion across notable acquisitions. Merck acquired Terns Pharmaceuticals for $5.7 billion to enhance its oncology pipeline, while Eli Lilly completed a $6.3 billion acquisition of Centessa Pharmaceuticals, and Biogen purchased Apellis Pharmaceuticals for $5.6 billion. Additionally, Kite Pharma received full FDA approval for its CAR-T therapy targeting mantle cell lymphoma, Revolution Medicines initiated a Phase 3 trial for pancreatic cancer, and Blackstone closed a record-breaking $6.3 billion life sciences fund. The surge in mergers and acquisitions emphasizes a strategic focus on enhancing pipelines and integrating advanced AI-driven technologies in drug development.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://oncodaily.com/techology/ai479711
